ChinaDaily Briefs

Daily Brief China: Midea Group Co Ltd A, Tencent, Hengan International Group, Geely Auto, Orient Overseas International, Jiangsu Hengrui Medicine, Samvardhana Motherson Automotive Systems Group BV and more

In today’s briefing:

  • Midea Group H Share Listing (300 HK): Trading Debut
  • Midea A/H Listing – Strong Demand for Quality Asset, Index Flows Could Help in the near Term
  • China Consumption Weekly (16 Sep 2024): Alibaba, Tencent, JD.com, Kuai, Hive Box
  • Technically Speaking, Breakouts and Breakdowns: HONG KONG (SEPTEMBER 13)
  • Geely (175 HK): Sales Volume Accelerated in August
  • Orient Overseas Intl (316 HK): Don’t Overlook Its Yield, Backed by Net Cash
  • Jiangsu Hengrui Medicine (600276.CH) – Share Price Is at Risk of Correction
  • Morning Views Asia: Meituan, Samvardhana Motherson International Ltd


Midea Group H Share Listing (300 HK): Trading Debut

By Arun George

  • Midea Group Co Ltd A (000333 CH) priced its H Share at HK$54.80 to raise HK$31,014 million (US$4.0 billion) in gross proceeds. The H Share will be listed tomorrow.
  • The H Share listing price implies an AH discount of 21.4% at the A Share price of RMB63.51. This compares to Haier Smart Home (6690 HK)‘s AH discount of 13.8%.
  • Futu grey market data shows that the H Shares closed 5.1% higher at HK$57.60. Our valuation analysis suggests that the H Share listing price is attractive.

Midea A/H Listing – Strong Demand for Quality Asset, Index Flows Could Help in the near Term

By Sumeet Singh

  • Midea Group Co Ltd A (000333 CH) raised around US$4.6bn in its H-share listing (including over-allocation), after the deal was upsized.
  • Midea Group is one of the world’s largest home appliance manufacturing companies with a presence in over 200 countries. Its A-shares have been listed since 2013.
  • We have covered the deal background in our previous notes. In this note, we talk about the trading dynamics.

China Consumption Weekly (16 Sep 2024): Alibaba, Tencent, JD.com, Kuai, Hive Box

By Ming Lu

  • Alibaba’s Taobao and Tmall apps decide to accept WeChat Pay, the online payment way from Tencent.
  • JD announced that it will raise employee salaries up to 20 months within two years.
  • Hive Box, the market dominator of parcel locker in China, submitted its IPO proposal.

Technically Speaking, Breakouts and Breakdowns: HONG KONG (SEPTEMBER 13)

By David Mudd

  • Hong Kong Conglomerate Sector is showing renewed strength with Materials and Energy under pressure.  HK market 30 day volatility at 5 year low as market continues to de-risk.
  • Hengan International Group (1044 HK) chart broke down from its Descending Triangle pattern after reporting its 1H24 results. J&T Global Express (1519 HK) broke down from its double bottom pattern.
  • China Galaxy Securities (H) (6881 HK) price relative to the MSCI China index broke to a new high.  The company reported good results in a difficult environment for China brokers.

Geely (175 HK): Sales Volume Accelerated in August

By Ming Lu

  • The sales volume growth rate began to accelerate in August.
  • Geely’s revenue grew strongly by 39% YoY in 2Q24 and 47% YoY in 1H24.
  • The operating margin had improved YoY for the past one year and a half.

Orient Overseas Intl (316 HK): Don’t Overlook Its Yield, Backed by Net Cash

By Osbert Tang, CFA

  • Orient Overseas International (316 HK) sits on decent yields of 12% for FY24 and 9.6% for FY25. Its net cash (66.2% of the share price) can support such dividends.
  • Despite the retreat from the recent peak, the spot freight rates are 9.7% and 145% higher than 1H24 and 2H23 respectively, pointing to better 2H24 earnings.
  • Operationally, it recorded the first YoY realised rate increase in 2Q24 after 6 quarters of consecutive decline. Its load factor also grew 2.3pp YoY in the quarter.

Jiangsu Hengrui Medicine (600276.CH) – Share Price Is at Risk of Correction

By Xinyao (Criss) Wang

  • On the surface, it seems that Hengrui’s performance growth in 24H1 is very high, but if excluding the upfront payment from Merck, the Company’s performance actually falls short of expectations.
  • Our forecast of revenue growth in 2024, 2025, 2026 (excluding Merck’s upfront payment) is 12% YoY, 8% YoY, 15% YoY, respectively. By 2026, Hengrui may still suffer from VBP.
  • Hengrui is overvalued and reasonable P/E is about 30 (or lower). We also don’t think Hengrui’s valuation should be higher than that of BeiGene. Current high valuation cannot be justified.

Morning Views Asia: Meituan, Samvardhana Motherson International Ltd

By Leonard Law, CFA

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars